Actively Recruiting
Heparins: Interference in Argatroban Measurement in Thromboembolic Disease
Led by University Hospital, Strasbourg, France · Updated on 2025-12-24
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how heparins, including unfractionated heparin (UFH) and low molecular weight heparins (LMWH), may interfere with measuring the anticoagulant activity of argatroban, a drug given after heparin therapy for suspected heparin-induced thrombocytopenia. This study focuses on understanding whether heparins affect the accuracy of a modified thrombin time test used to monitor argatroban's anti-IIa activity, an important factor since both clotting and bleeding risks exist in this context. This observational study involves patients anticoagulated with UFH or LMWH whose blood samples are analyzed at the Hematology Laboratory of Strasbourg University Hospitals. The study does not involve new treatments but monitors routine measurements of anti-Xa and anti-IIa activity to see if heparins impact the test results for argatroban. Participants provide blood samples during routine care, which are tested for anti-Xa activity and the anti-IIa activity of argatroban. Researchers will analyze the correlation between measurements to assess interference. The main outcome is measured one hour after analysis using statistical correlation tests. The study aims to improve how anticoagulation is monitored in patients with thromboembolic disease. Participation duration and follow-up details are not specified.
CONDITIONS
Brief Title
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (≥ 18 years)
- Patient anticoagulated with unfractionated heparin or low molecular weight heparin
- Sample sent to the Hematology Laboratory of the University Hospitals of Strasbourg and analyzed for anti-Xa activity in routine care
You will not qualify if you...
- Patient receiving an anticoagulant other than unfractionated heparin or low molecular weight heparin
- Insufficient sample volume
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Ongoing during routine care
Participants who are anticoagulated with unfractionated heparin or low molecular weight heparin have blood samples collected and sent to the laboratory for anti-Xa activity analysis as part of routine care.
Samples collected during routine healthcare visits
Trial Site Locations
Total: 1 location
1
Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Agathe HERB, PharmD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here